Company Encyclopedia
View More
name
XUANZHUBIO-B
02575.HK
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates includes Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor.
1.371 T
02575.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hong Kong Stock Movement: Competition in the innovative drug industry intensifies, XUANZHUBIO falls 10.19%

    XUANZHUBIO-B fell 10.19%; CSPC Pharmaceutical Group fell 2.25%, with a transaction volume of HKD 460 million; China Biologic Products fell 2.43%, with a transaction volume of HKD 329 million; Hansoh Pharmaceutical had a transaction volume of HKD 187 million; Heng Rui Medicine fell 3.17%, with a market value of HKD 465.6 billion

    HK Stock Movers Tracker·
    HK
    02575
    -0.63%
    HK Stock Movers Tracker·
    HK
    02575
    -0.63%

    The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

    On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

    Zhitong·
    HK
    02575
    -0.63%
    HK
    01228
    -4.95%
    HK
    03681
    -3.01%
    Zhitong·
    HK
    02575
    -0.63%
    HK
    01228
    -4.95%
    HK
    03681
    -3.01%

    Understanding the Market | XUANZHUBIO-B rises over 5% again as the company presents clinical phase III research data on palbociclib for breast cancer at the ESMO annual meeting

    XUANZHUBIO-B's stock price rose over 5% again, with an increase of 5.12% as of the time of writing, reported at HKD 62.65, with a transaction volume of HKD 23.5573 million. The company presented clinical phase III research data on the combination of palbociclib with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology (ESMO). Based on the interim data from this study, the National Medical Products Administration of China accepted the new drug application on May 14, 2025

    Zhitong·
    HK
    02575
    -0.63%
    Zhitong·
    HK
    02575
    -0.63%

    Zhitong Hong Kong Stock 52-Week New Highs and Lows Statistics | October 22

    As of October 22, there are 34 stocks in the Hong Kong stock market that have reached a 52-week high. HAINA INTEL ranks first with a high rate of 37.57%, followed by XUANZHUBIO-B and 1957 & CO. with 35.16% and 28.57%, respectively. Other outstanding stocks include FUTONG TECH and STD DEV GROUP

    Zhitong·
    HK
    02575
    -0.63%
    HK
    08495
    +7.69%
    HK
    00465
    -12.28%
    Zhitong·
    HK
    02575
    -0.63%
    HK
    08495
    +7.69%
    HK
    00465
    -12.28%

    Hong Kong Stock Movement: Innovative Drug Approval Boosts XUANZHUBIO-B by 22.75%, Market Confidence Significantly Increases

    XUANZHUBIO-B surged 22.75%; CSPC Pharmaceutical Group fell 2.91%, with a transaction volume of HKD 561 million; China Biologic Products fell 1.76%, with a transaction volume of HKD 300 million; Heng Rui Medicine fell 0.70%, with a transaction volume of HKD 139 million; Hansoh Pharmaceutical fell 0.95%, with a market value of HKD 215.6 billion

    HK Stock Movers Tracker·
    HK
    02575
    -0.63%
    HK Stock Movers Tracker·
    HK
    02575
    -0.63%